Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 16, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 16, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/16/14 - Acceleron to Host Educational Webcast Series with Clinical Thought Leaders
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that it plans to host and webcast a series of online seminars with thought-leading experts in diseases for which sotatercept and luspatercept are...
9/16/14 - ACCU-CHEK Aviva Expert, the first and only stand-alone blood glucose meter system with a built-in insulin calculator, is now available
Roche announced today that Roche's ACCU-CHEK Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration, is now available by prescription. In the United States, approximately 6 million people take insulin to help manage their diabetes. 2 Many peo
9/16/14 - Actinium to Present at the 21st Annual BioCentury NewsMakers Conference on Friday, September 26th
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Members of the investment community who are interested in meeting with management should contact Evan Smith, CFA of Actinium Pharmaceuticals at 840-5442 or...
9/16/14 - ADMA Biologics: Korean Ministry of Food and Drug Safety Approves ADMA BioCenters [Health & Beauty Close - Up]
ADMA Biologics reported that its subsidiary, ADMA BioCenters in Norcross, Ga., received approval from the Korean Ministry of Food and Drug Safety for the sale of source plasma into South Korea. "This approval further enhances our existing global presence as a source plasma provider, which includes the U.S., Europe and now South Korea. ADMA BioCent
9/16/14 - Agile Initiates Phase 3 SECURE Study for Twirla(TM)
Agile Therapeutics, Inc., a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the initiation of its Phase 3 study called SECURE. "In planning the SECURE study, we focused on identifying experienced clinical sites with expertise in conductin
9/16/14 - Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors [Global Data Point]
Mr. Renaud served as President, Chief Executive Officer and Director of Idenix Pharmaceuticals, Inc. from October 2010 until the company's recent acquisition by Merck. Before joining Idenix, Mr. Renaud served as Senior Vice President and Chief Financial Officer of Keryx Biopharmaceuticals, Inc. Previously, Mr. Renaud was also a Senior Research Anal
9/16/14 - Alnylam Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Sept. 16 Alnylam Pharmaceuticals, Cambridge, Massachusetts, has been assigned a patent developed by four co-inventors for "carbohydrate conjugates as delivery agents for oligonucleotides." The co-inventors are Muthiah Manoharan, Cambridge, Massachusetts, Kallanthottathil G. Rajeev, Cambridge, Massachusetts, Narayanannair K. Jayap
9/16/14 - AMAG Pharmaceuticals Appoints Judith Johnson, M.D. as Vice President of Pharmacovigilance and Pharmacoepidemiology
AMAG Pharmaceuticals, Inc. today announced that Judith Johnson, M.D., has rejoined the company as vice president of pharmacovigilance and pharmacoepidemiology. Over the past ten years, Dr. Johnson has held leadership roles in pharmacovigilance and drug safety at such biopharmaceutical companies as EMD Serono, Inc., AMAG, Genzyme and Parexel.
9/16/14 - Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study
Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today its continued commitment to completing the ongoing REDUCE-IT cardiovascular outcomes study. Amarin has always been scientifically committed to the REDUCE-IT cardiovascular...
9/16/14 - Aphios Awarded Grant for Developing cGMP Process for CBD Using Green Drug Manufacturing Technology
Aphios Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute on Drug Abuse, NIH to develop a process for manufacturing cGMP cannabidiol using its green drug manufacturing technology. Trevor P. Castor, CEO and Principal Investigator on this grant We believe that CBD can be cost-effectively
9/16/14 - Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency
The full interim results will be presented at the 7th International Congress of the GRS and IGF Society, being held October 15-18, 2014, in Singapore. "It has been demonstrated that patients who do not comply with the daily injection regimen of currently available growth hormone therapies suffer from suboptimal treatment outcomes," commented Paul
9/16/14 - AstraZeneca Says US FDA Approves Opioid-Induced Constipation Treatment
LONDON- AstraZeneca PLC Tuesday said the US Food and Drug Administration has approved its MOVANTIK tablets C-II for the treatment of opioid-induced constipation, in adult patients with chronic, non-cancer pain. According to AstraZeneca, opioids play an important role in chronic pain relief and millions of patients are treated with them in the US ea
9/16/14 - AVNR Excites Investors, MRK To File Odanacatib NDA In 2015, Watch Out For ZSPH
WHITEHOUSE STATION- Avanir Pharmaceuticals Inc. rose more than 85 percent on Monday following the release of positive phase II trial data of AVP-923, the company's investigational drug for the treatment of agitation in patients with Alzheimer's disease. Avanir plans to request a meeting with both the FDA and the European Medicines Agency to discuss
9/16/14 - Baxter International to Launch Biopharmaceutical Company [Health & Beauty Close - Up]
Baxter International Inc. reported that Baxalta Inc. will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015. Baxter International will continue trading on the NYSE under the symbol BAX. "The naming of Baxalta is the latest milestone on our journey to becoming a separate, independent company,"
9/16/14 - Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer who have rising Prostat
9/16/14 - Big cities take aim at prescription painkillers
The heightened rhetoric comes as Chicago tries to recover millions in health care costs from opioid drugmakers, alleging that companies deliberately misled the public about the risks of their drugs. On Tuesday, health commissioners from Chicago, New York and Boston came to Washington to lobby Congress and the White House on efforts to combat prescr
9/16/14 - Biotech Stocks Technical Data - Medivation, Galectin Therapeutics, Ironwood Pharma, Achillion Pharma, and PDL BioPharma
Investor-Edge has initiated coverage on the following equities: Medivation Inc., Galectin Therapeutics Inc., Ironwood Pharmaceuticals Inc., Achillion Pharmaceuticals Inc., and PDL BioPharma Inc.. Medivation Inc.' s stock finished Monday's session 2.37% lower at $93.27. Over the last one month and over the previous three months, Medivation Inc.' s s
9/16/14 - Can-Fite Issued Japanese Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
By a News Reporter-Staff News Editor at China Weekly News Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, announced the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanes
9/16/14 - Celator Pharmaceuticals Inc. (NASDAQ: CPXX) to Ring The NASDAQ Stock Market Closing Bell
Celator Pharmaceuticals Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, will visit the NASDAQ MarketSite in Times Square. Scott Jackson, will ring the Closing Bell to celebrate the Company's achievements since it started trading on The NASDAQ Stock Market last November. NASDAQ MarketSite 4 Times Square
9/16/14 - CNPR Certification Celebrates 15 Years of Educational Success and Industry Leadership
On September 19, nearly 75 education leaders, executives and CEOs will come together for a leadership summit to focus on new topics for high-impact, pharmaceutical sales strategies to advance results for all CNPR students and increase the value of the CNPR educational program. Several pharmaceutical industry education leaders will also speak at the
9/16/14 - Concert Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Sept. 16 Concert Pharmaceuticals, Lexington, Massachusetts, has been assigned a patent developed by three co-inventors for "synthesis of deuterated catechols and benzo dioxoles and derivatives thereof." The co-inventors are I. Robert Silverman, Arlington, Massachusetts, Andrew D. Jones, Needham, Massachusetts, and Robert E. Zelle
9/16/14 - ContraFect Corporation's Universal Influenza Treatment Receives SBIR Funding
ContraFect Corporation, a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced that CF-404, its universal influenza treatment, received a $3.3 million, 3.5 year Advanced Technology Fast Track Small Business Innovation...
9/16/14 - Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014
Convoy Therapeutics, Inc., a specialty biopharmaceutical company that develops safe and effective products to treat patients directly at the site of disease through the use of a proprietary SPACE? Technology Platform announced today that John Muraski, Ph.D., Chief Executive Officer and President will present at the White Hat Life Science Investor
9/16/14 - CSL Behring Announces Last Patient Treated in Phase III Study of Fibrinogen Concentrate to Control Bleeding During Aortic Aneurysm Surgery
CSL Behring announced today that the last patient has been treated as part of the REPLACE Phase III clinical trial. Niels Rahe-Meyer, Professor and Head of the Department of Anesthesiology and Intensive Care, Franziskus Hospital, Bielefeld, Germany and coordinating investigator of the study. "At CSL Behring, we are committed to improving the liv
9/16/14 - Data on Melanomas Described by Researchers at University of Montpellier I [Comparative evaluation of the new FDA approved THxID ?-BRAF test with high...
Data on Melanomas Described by Researchers at University of Montpellier I. By a News Reporter-Staff News Editor at Cancer Weekly Current study results on Melanomas have been published. Our news journalists obtained a quote from the research from the University of Montpellier I, "We assessed the new CE THxID?- BRAF diagnostic test, which is also
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415